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Abstract
Cancer  cells  are  remarkably  resilient  to  therapies  aimed at  their  elimination.  The
exploration of pathways that sustain cancer cells and that allow cancer cells to become
resistant has revealed new avenues for chemotherapeutic development, as well as rational
approaches  to  combination  therapies  based on existing  treatment  options.  Several
signaling pathways, such as Wnt, phosphoinositide 3-kinase (PI3K), and Ras-Raf-MEK,
constitute integrated networks that work together to maintain cellular homeostasis under
basal conditions and to drive cell-mass accumulation and cell cycle progression in the
presence of appropriate mitogenic stimuli. During cancer development, these path‐
ways are corrupted in malignant cells to maintain viability and proliferative activity under
environmentally stressful conditions such as limited growth factors, oxygen, and nutrients
that drive normal cells into quiescence or death. Importantly, dysfunction within any one
of these pathways results in compensatory responses from the other networks. Thus,
biological research is gradually shifting toward more general approaches that target entire
pathways rather than isolated components and integrate those pathways into biologi‐
cal networks.
Keywords: cancer resistance, autophagy, hypoxia, survival signaling pathways, colon
cancer
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1. Introduction
The inherent or developed resistance of many cancer cells to chemotherapy, targeted types of
therapy, and irradiation is the primary cause for treatment failure in clinical oncology. Through
basic research efforts aimed at gaining a better understanding of the mechanisms responsible
for these effects, it is hoped that more effective strategies to manage this disease will be developed.
Wnt signaling has been recognized as one of the most important contributors to malignant
transformation in many types of solid tumors. Canonical Wnt signaling is altered in most cases
of colorectal cancer (CRC). Indeed, a great amount of experimental evidence has shown that
mutations in the adenomatous polyposis coli (APC) gene, a key negative modulator of
canonical Wnt signaling, trigger the molecular pathogenesis of this type of cancer [1, 2]. The
Wnt pathway has also been demonstrated to play an important role in the regulation of adult
stem cell systems, and canonical Wnt signaling regulates the self-renewal and maintenance of
both stem and cancer stem cells (CSCs). Cross talk has been reported between canonical Wnt
signaling and hypoxia-inducible factor (HIF) signaling in tumor progression and metastasis
[3]. However, the molecular mechanisms involved in this cross talk remain poorly understood.
Diminished oxygen availability (hypoxia) with the hypoxia-inducible factors (HIFs) mediating
adaptation to it causes autophagy establishment, particularly in RAS-driven and BRAF-driven
cancers, such as in most colorectal carcinomas. However, the relevance of the relation between
HIFs and autophagy in drug resistance is not well understood. We have examined the effects
of stable knockdown of HIF-1α or HIF-2α expression on malignant phenotype maintenance
and in the canonical Wnt activation (β-catenin dependent). Our results indicated that although
both HIF-1α and HIF-2α are essential for stemness and malignancy maintenance, these two
proteins exert different effects and play opposing roles in canonical Wnt signaling [3]. We have
also examined the effects of HIFs silencing on autophagy and drug resistance displayed by
cancer cells. In agreement with other groups, we have observed that cancer cells exhibit high
basal levels of autophagy and co-expression of HIF-1α and HIF-2α, compared with control
nonmalignant cells and that the combination of mTOR inhibition with the autophagy inhibitor
hydroxychloroquine (HCQ) dramatically induced cell death via apoptosis [4].
In addition, it has been demonstrated recently that challenging cancer cells with stresses that
they would typically encounter during tumor progression or as a part of a therapeutic regiment
to treat or manage the disease, including chemotherapeutic agents, gamma irradiation, and
hypoxic and serum-limiting conditions, increase the rate of microvesicles (MVs, referred also
as oncosomes) formation and shedding by cells [5, 6]. These MVs are secreted from numerous
types of cells and function in intercellular communication by transporting intracellular
contents, such as protein, mRNA, and microRNAs (miRNAs) [7]. Oncosomes secreted by
cancer cells may play an important role in cancer progression by promoting angiogenesis,
neutrophil infiltration, and the education of bone marrow-derived cells [8]. Indeed, recent
findings suggest that MVs can promote cell survival and contribute to drug resistance.
In this review we focus on the molecular mechanisms whereby cancer cells develop resistance
to antineoplastic drugs, particularly focused in the cell signaling pathways involved. A better
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understanding of the mechanisms that drive such resistance would enable the development
of approaches to overcome it.
2. Survival signaling pathways: highly integrated cellular networks
Targeted blockade of aberrantly activated signaling pathways is an attractive therapeutic
strategy for solid tumors, but drug resistance is common. Several selective inhibitors, partic‐
ularly against kinases and receptor tyrosine kinases (RTKs), have shown promising initial
efficacy [9]; however, with few exceptions, the duration of response is limited; drug resistance
rapidly emerges. This underscores the difficulty of successfully treating an adept, heteroge‐
neous disease with a single targeted therapy and highlights the fact that monotherapy is often
not a tractable long-term therapeutic approach.
Resistance mechanisms can include alterations in the drug target itself, the pathway in which
the target signals, or a parallel pathway that can alleviate the pressure on the cell due to
blockade of the target [10]. Alternatively, drug resistance may be mediated by epigenetic
reprogramming [11], by epithelial-to-mesenchymal transition (EMT) [12], or by emergence of
a less differentiated, progenitor cell type [13]. Inducers of EMT, such as growth factors,
transforming growth factor beta (TGFβ), and Wnt ligands, induces the expression of a gene
program that leads to the suppression of the expression of the cell adhesion protein E-cadherin
via the expression of transcriptional repressors such as Snail, Slug, Zeb1, Zeb2, and Twist.
Besides these genes, other typical markers of EMT are N-cadherin, vimentin, and fibronectin-1,
which are usually expressed in mesenchymal cells [3].
The emergence of acquired resistance to targeted therapy against cancer is very common and
the most frequent cause of treatment failure in cancer patients. This resistance can be mediated
by signaling pathway reactivation [14] or by genetic or epigenetic events occurring within
cancer cells [10]. Ultimately, these events lead to the activation of growth and survival signaling
pathways within cancer cells that enable them to survive the stressful conditions. However,
for most drugs, the identities of potential resistance pathways are unknown. The signaling
pathways more frequently associated with cancer resistance to treatment are the following:
2.1. The PI3K signaling network
The phosphoinositide 3-kinase (PI3K) signaling pathway, which lies downstream of various
growth factor receptor tyrosine kinases, including the EGFR, is often aberrantly activated in
human cancers. It plays critical roles in the regulation of cell growth, proliferation, differen‐
tiation, motility, survival, and intracellular trafficking. When deregulated, it is a major driver
of tissue hyperplasia, oncogenesis [15], and is implicated in many aspects of tumorigenesis,
including inappropriate cellular proliferation, angiogenesis, metastasis, and resistance to cell
death.
There are three classes of PI3K enzymes: the Class I PI3Ks play a central role in the transmission
of regulatory signals through the metabolism-signaling supernetwork [15]. Class I PI3Ks are
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expressed as heterodimers consisting of four p110 catalytic subunits and one of two p85
regulatory subunits and are activated primarily by tyrosine kinase signaling pathways and
heterotrimeric G protein-coupled signaling pathways. Upon activation, Class I PI3Ks prefer‐
entially phosphorylate PI-4,5-P2 to yield the second messenger PI-3,4,5-P3 [15]. The activation
of PI3K activation is dampened by the lipid phosphatase PTEN, which dephosphorylates
PI-3,4,5-P3 to regenerate PI-4,5-P2, thereby disengaging the proximal signaling proteins from
the network. The local accumulation of PI-3,4,5-P3 at the inner leaflet of the plasma membrane
attracts proteins containing pleckstrin homology (PH) domains, which bind PI-3,4,5-P3 and
PI-3,4-P2 to act as proximal signal transducers in the PI3K pathway [15] (Figure 1).
Figure 1. The PI3K and AMPK pathways are shown. Different members of the PI3K pathway increase apoptosis resist‐
ance. AMPK also regulates cellular metabolism by phosphorylating directly the tumor suppressor tuberous sclerosis 1
and 2 complex (TSC1/TSC2) to activate mTOR via Rheb GTPase.
The best-studied member of this set of PH domain-containing proteins is the serine-threonine
kinase AKT, which is juxtaposed with its upstream activating protein kinase, PDK1. AKT is
activated through phosphorylation of its threonine 308 residue by PDK1 and of serine 473 by
mTOR complex 2 to mediate many PI3K responses, including growth, metabolism, survival,
and glucose homeostasis [16]. AKT promotes apoptosis resistance by phosphorylating and
thereby inhibiting proapoptotic substrates and profoundly influences cellular metabolism
through its direct effects on metabolic enzymes and, more indirectly, through the stimulation
of mTOR complex 1 (mTORC1) activity (Figure 1).
The PI3K-AKT pathway is central to the integration of growth factor-derived signals and
nutrient availability with anabolic metabolism, growth, and cell cycle progression in multi‐
cellular organisms. In diseases such as cancer, this pathway is reprogrammed to fuel stress
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resistance and uncontrolled growth and couples growth factors and other hormonal stimuli
to the metabolic and autophagy networks.
2.2. The Wnt pathway
Wnt signaling is a key pathway in embryonic development and adult homeostasis and
aberrant activation of this pathway plays an important role in the development of many human
cancer types [1, 2]. Indeed, aberrant Wnt signaling is a hallmark of the majority of colorectal
cancers and it is implicated in maintenance of tumor-initiating cells, drug resistance, tumor
progression, and metastasis.
Canonical Wnt signals are transduced through Frizzled family receptors and LRP5/LRP6 co-
receptor to regulate the phosphorylation and degradation of the transcription co-activator β-
catenin (Figure 2). Noncanonical Wnt signals are transduced independently of β-catenin
through Frizzled family receptors and ROR2/RYK co-receptors to the Rho family guanosine
triphosphatases, c-jun-NH2-terminal kinase, or the Ca2+-dependent signaling cascades.
Figure 2. The canonical Wnt pathway shown controls β-catenin intracellular levels and localization. When it is activat‐
ed, β-catenin is stabilized and translocated to the nucleus to bind TCF transcription factor and activate Wnt-responsive
genes. Noncanonical Wnt pathway transduces signals in a β-catenin-independent manner and its activation has been
associated with aggressive malignant phenotype.
In the absence of Wnt ligands, β-catenin is assembled into the so-called destruction complex
assembled by adenomatous polyposis coli (APC) tumor suppressor, axin, glycogen synthase
kinase-3β (GSK-3β), and casein kinase 1 (CK1). This complex promotes phosphorylation of β-
catenin that targets it for ubiquitination and subsequent proteolysis via the proteasome [2, 3].
Upon Wnt stimulation β-catenin breakdown is inhibited, thereby causing its accumulation and
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entry to the nucleus, to activate Wnt target genes [2]. In noncanonical Wnt pathways, Wnt
signals are transduced independently of β-catenin. The best-studied noncanonical Wnt
pathways are planar cell polarity (PCP) pathway and Ca2+ pathway, which play central roles
in developmental morphogenesis, cell polarity, and cell migration. In Wnt/Ca2+ pathway, Wnt-
Frizzled (Fzd) binding activates phospholipase C (PLC) via G proteins, producing an increase
of intracellular Ca2+ concentration and the activation of downstream effectors including protein
kinase C, as it can be seen in Figure 2 [1].
A great effort in developing selective drugs to target components of the Wnt pathway,
particularly the β-catenin-dependent pathway, with anticancer activity, is underway but only
a few of them have reached phase I clinical trials. In this respect, in models of KRAS-mutant
colorectal cancer, it has been found by RNA-Seq data analysis for differential expression of
canonical Wnt target genes that resistant cells display increased Wnt-β-catenin transcriptional
activity [10], but there is also evidence, using this technique, that activation of noncanonical
Wnt signaling exists in cancer-resistant cells and in different subsets of circulating tumor cells
(CTCs) obtained from patients [17].
2.3. Ras-Raf-MEK signaling pathway
As mentioned before, oncogenic drivers often elicit a strong tumor dependence on the pathway
that the driver controls, leading to the so-called pathway addiction. One such oncogenic driver
that elicits a pathway addiction is mutant KRAS which is directly implicated in the simplified
linear RAS-RAF-MEK ERK (extracellular signal-regulated kinase) signaling axis, as well as the
Figure 3. The Ras-Raf-MEK and NF-kB signaling pathways promote resistance. Mutations and amplification of Ras-
Raf-MEK are frequently found in colorectal cancer allowing the development of resistance to treatment via autophagy
activation. NF-kB upregulates Beclin 1 expression allowing positive regulation of autophagy. On the other hand,
HIF-1α also modulates Beclin 1. IKK can promote the autophagy in an NF-kB-dependent manner.
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PI3K-mTOR axis [10]. Mutations within RAS-Raf-Mex pathway have frequently detected in
colorectal cancer, being BRAFV660E the most frequently found (Figure 3).
Little et al. [18] and Corcoran et al. [19] examined the mechanisms whereby colorectal cancers
develop resistance. Both studies focused on the effects produced by inhibition of MEK
(mitogen-activated or extracellular signal-regulated protein kinase kinase), which is a
downstream effector of the oncogene BRAF or KRAS [9]. Both groups found that resistance
arose through amplification of the driving oncogene (BRAF or KRAS) rather than through
amplification or mutation of the targeted kinase itself (MEK).
There is also evidence that BRAF oncogene induces the expression of key autophagic markers,
like microtubule-associated protein 1 light chain 3 (LC3) and Beclin 1 (BECN1) in colorectal
tumor cells. Goulielmaki et al. [20] provided strong evidence that pretreatment with the
autophagy inhibitor 3-methyl adenine (3-MA) followed by its combination with BRAFV600E
targeting drug PLX4720 can synergistically sensitize resistant colorectal tumors.
2.4. LKB1/AMPK pathway
AMPK is the central metabolic sensor activated by elevated AMP/ATP ratios. LKB1 is a human
tumor suppressor kinase that is a crucial upstream molecule for the activation of AMPK and
hence links cell metabolism to growth control and cell polarity [21]. During nutrient and energy
depletion, ATP becomes depleted while the AMP/ATP ratio rises, activating the energy-
sensing kinase, LKB1, which consequently activates AMPK. The AMPK regulates mTORC1
by direct phosphorylation of the tumor suppressor tuberous sclerosis complex 2 (TSC2) to
activate mTORC1 via Rheb GTPase (Figure 1).
2.5. Nuclear factor-kB
Aberrant activation of the nuclear factor kappa B (NF-kB) family of dimeric transcription
factors has been linked to most cellular processes in tumor evolution including inflammation,
transformation, proliferation, invasion, metastasis, and chemoresistance [22]. The most
common constitutively active form reported in human malignancies is the p50/RelA dimer,
but other forms, such as p50/p50, p52/p52, p52/RelA, p50/c-Rel, c-Rel/c-Rel, p52/RelB, and p50/
RelB, have also been identified [22]. In normal inactivated state, this transcription factor is
sequestered in the cytoplasm by its inhibitor IkB (Figure 3). In order to be activated, IkB must
be phosphorylated by the IkB kinase (IKK) complex and degraded via proteasome, causing
the liberation and translocation of NF-kB into the nucleus where it modulates gene expression.
Experimental evidence demonstrates that NF-kB can positively regulate autophagy (Fig‐
ure 3). For instance, RelA upregulates Beclin 1 expression through direct binding to the NF-
kB-binding site on the Beclin 1 gene promoter to induce autophagy [23]. The multilevel control
of autophagy by the IKK/IkB/NF-kB axis is also highlighted by the finding that IKK may also
promote the autophagic pathway in a manner independent of NF-kB. All these findings
support the idea that NF-kB activation promotes autophagy.
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3. Metabolic stress resistance
Metabolism is the process by which cells convert relatively simple extracellular nutrients into
energy and building blocks necessary for their growth and survival. In cancer cells, metabolism
is dramatically altered compared with normal cells.
Metabolic stress in tumors arises from multiple factors, including cell growth and proliferation
in the setting of fluctuating supplies of oxygen and nutrients. Lack of adequate blood supply
leads to several stress types in tumors: hypoxia, nutrient deprivation, and the accumulation
of metabolic waste products [15]. These stress types are relieved in part by the over-expression
of hypoxia-inducible factors (HIFs) to release proangiogenic factors for the construction of a
tumor-associated vasculature. Persistent metabolic stress in tumors provokes the rewiring of
the metabolic network to accommodate the stressful tumor microenvironment [17].
Metabolic reprogramming is a hallmark of cancer cells and is used by them for growth and
survival. Their metabolism is highly dependent on glycolysis instead of mitochondrial
oxidative phosphorylation, regardless of oxygen availability, a process termed as Warburg
effect [15]. Glycolysis alone, although relatively inefficient means to produce ATP, provides a
mechanism for rapid energy generation and a source of carbon for macromolecular synthesis.
In addition, the shift to glycolytic metabolism allows rapidly proliferating cells to support both
energy production and biosynthesis [15]. In addition, the glycolytic pathway generates
metabolites that can be efficiently diverted into pathways that support nucleotide and amino
acid biosynthesis in cycling cells [15].
One interesting facet, from a chemotherapeutic point of view, is that, in a large number of
cases, cells undergoing a Warburg effect exhibit a marked dependence upon glutamine, to the
extent that these cells are referred to as being “glutamine addicted” [24]. Glutamine addiction
arises from the need for extracellular glutamine to be consumed for anaplerotic input in the
citric acid cycle, which accounts for the majority of the bioenergetic needs of normal (non‐
transformed) cells. Cancer cells rely heavily on glutamine as a source of carbon and nitrogen
for the synthesis of ATP, proteins, lipids, nucleic acids, and the antioxidant glutathione.
Expression of the Wnt target MYC proto-oncogene increases glutamine uptake by stimulating
expression of the glutamine transporters. At the same time, MYC increases the levels of
glutaminase 1 (GLS1), the enzyme that converts glutamine to glutamate [15, 24].
During oncogenesis, the survival signaling pathways such as PI3K, intermediate metabolism,
and autophagy constitute the metabolism-signaling supernetwork reprogrammed in ways
that support aberrant cell growth, proliferation, and stress resistance. Indeed, emerging
evidence suggests that autophagy is an important source of amino acids that supports the
stressed cell’s biosynthetic and bioenergetic needs.
4. Hypoxia and drug resistance
Diminished oxygen availability (hypoxia) is a hallmark of the tumor microenvironment. A
major regulator of cellular adaptation to hypoxia is the hypoxia-inducible factor (HIF) family
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of transcription factors, which play key roles in many crucial aspects of cancer biology
including angiogenesis, stem cell maintenance, metabolic reprogramming, resistance to
apoptosis, autocrine growth factor signaling, the epithelial-mesenchymal transition (EMT)
program, genetic instability, invasion, metastasis, and radiation resistance [25] (Figure 4). HIFs
also cause autophagy establishment, particularly in RAS-driven and BRAF-driven cancers,
such as most colorectal carcinomas (Figure 4). However, the relevance of the relation between
HIFs and autophagy in drug resistance is not well understood.
Figure 4. HIF target genes. The cellular processes regulated by HIF-1α and HIF-2α genes are indicated and also the
target genes for each one.
HIFs are heterodimeric transcription factors consisting of an O2-sensitive subunit HIF-α and
a stable subunit HIF-β (or ARNT) that are expressed constitutively at the transcriptional and
translational levels (Figure 5). In mammals, three HIF-α isoforms have been identified but
HIF-1α and HIF-2α are the two best-studied members of the HIF-α family. Under normoxic
conditions, the cellular stability and activity of HIF-α subunits are highly dependent on oxygen
supply. Prolyl hydroxylases hydroxylate key proline residues on HIFs, which allows them to
interact with the von Hippel-Lindau (pVHL) tumor suppressor, which is a component of an
E3 ubiquitin ligase complex that targets HIF-α for proteasomal degradation (Figure 5).
Hypoxic conditions stabilize HIF-α by inhibiting its hydroxylation and proteasomal degrada‐
tion, making HIF-α capable to translocate to the nucleus and dimerize with ARNT activating
the transcription of hypoxia-associated genes [25, 26]. Importantly, high levels of HIFs
expression have also been detected in tumor cells in the absence of hypoxia (Figure 5) because
the sustained oncogenic signaling mediated by growth factors in cancer cells can induce HIF-
α expression through O2-independent mechanisms, including increased transcription and/or
translation of HIF-α mRNA [27, 28]. In this respect, we have reported that colon carcinoma
cells co-express HIF-1α and HIF-2α under normoxic conditions, in contrast to nonmalignant
colon cells, which do not express these factors under these conditions [3].
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Figure 5. HIF activation. HIFs are heterodimeric transcription factors subjected to O2-sensitive or O2-independent
mode of activation, as indicated in the figure. Both types of regulation converge in HIF protein stabilization, which can
enter to the nucleus to bind HIF-1β at HIF-responsive elements (HRE) to activate target genes.
Hypoxia can lead to therapeutic resistance through diverse mechanisms [29, 30]: (1) direct
effects due to the requirement of some drugs and radiation of lack of oxygen in order to be
maximally cytotoxic, (2) indirect effects by altering cellular metabolism to decrease drug
cytotoxicity, and (3) enhanced genetic instability which in turn leads to more rapid induction
of drug resistance in tumor cells [29, 30]. HIF-1α and to a lesser extent HIF-2α have been
associated with radio- and chemotherapy failure for decades [30] and interference with HIF
function holds great promise to improve future anticancer therapy.
4.1. Hypoxia-induced drug resistance through metabolic alteration
One of the possible mechanisms of resistance to anticancer therapy in hypoxic tumor is the
switching of cellular metabolism from oxidative phosphorylation to aerobic glycolysis
(Warburg effect), a hallmark of cancer cells. As a result, cancer cells eventually develop a
system that uses cytoplasmic glycolysis to generate ATP instead of mitochondrial oxidative
respiration, even in the presence of oxygen. Several reports have indicated that activation of
the HIF-1α signaling pathway under glucose deprivation induces resistance to cell death by
apoptosis in human colon cancer cells and that targeting the HIF-1α signaling pathway may
provide an effective way to treat resistant cancers to conventional therapy [31].
4.2. Hypoxia-induced drug resistance through increased drug efflux
HIF-1α upregulation has been shown to induce expression of drug efflux transporters, to alter
the activity of DNA repair mechanisms, and to shift the balance between pro- and antiapoptotic
factors toward cell survival [32].
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Drug efflux is an important mechanism to chemoresistance in many solid tumors, including
colon cancer. The multidrug resistance 1 (MDR1) gene, encoding the membrane-resident P-
glycoprotein (P-gp) that belongs to a family of ATP-binding cassette (ABC) transporters, has
been found to be a HIF-1α target gene [33]. The multidrug resistance-associated protein 1
(MRP1) is another ABC transporter encoded by the ABCC1/MRP1 gene that confers cellular
resistance to a broad range of structurally and functionally chemotherapeutic agents. Recently,
it has been demonstrated that MRP1 is a downstream target gene of HIF-1α in human colon
cancer LoVo cells. Genetic inhibition of HIF-1α by siRNA and dominant-negative HIF-1α
reduced the expression of MRP1, which provides a potential novel mechanism for HIF-1α-
mediated drug resistance [34].
4.3. Hypoxia-induced drug resistance through inhibition of apoptotic pathways and
induction of autophagy
Defective apoptosis and/or changes in cell cycle regulation represent pivotal causes for drug
resistance [35]. It has been proposed that increased cell survival, due to a shift favoring
antiapoptotic pathways, is a primary mechanism of hypoxia-induced drug resistance [36]. In
the vast majority of transformed cells, HIF-1α functions as a suppressor of apoptosis and
functional interference with HIF-1α results in enhanced cell death upon treatment with
chemotherapeutic agents in tumors of different origins [26]. Through the inhibition of
proapoptotic and induction of antiapoptotic genes, HIF-1α can inhibit apoptosis and promote
tumor cell survival in chemotherapy-treated cancer cells.
In colorectal cancer, the combination therapy of rapamycin, inhibitor of mTOR which regulates
autophagy, and irinotecan, which is able to inhibit the accumulation of HIF-1α, has been
reported to induce massive death of colon cancer cells under hypoxic, but not normoxic
conditions in vitro, and a great reduction of tumor volume in vivo [37].
Enhanced autophagy has been associated with the elevated level of HIF-1α in several cancer
types. In this regard, it has been observed that hypoxia-mediated failure of cytotoxic treatment
in vitro can be conferred via HIF-1α-dependent induction of autophagy [14], but the relevance
of the intriguing relation between HIF-1α and autophagy for drug resistance is still not known.
5. Role of autophagy in stress resistance
Autophagy is a term derived from the Greek words “auto” (self) and “phagy” (to eat) and
refers to a multistep lysosomal degradation process in which a cell degrades damaged
organelles and longlived proteins to maintain cellular homeostasis, particularly during
exposure to stressful conditions. Three forms of autophagy have been identified based upon
the mode of delivery to the lysosome, namely, macroautophagy, microautophagy, and
chaperone-mediated autophagy. Macroautophagy (autophagy), the best characterized, is a
major regulated catabolic process that involves the delivery of cytoplasmic cargo sequestered
inside double-membrane vesicles to the lysosome [38]. The other two forms, microautophagy
and chaperone-mediated autophagy, involve a direct membrane invagination to engulf
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damaged proteins and the translocation of soluble cytosolic proteins by chaperone-dependent
selection across the lysosomal membrane, respectively [39]. Thirty-six genes (ATGs for
AuTophaGy), have been identified that are required for the autophagy process to occur.
Dysregulation of autophagy, which alters the rate of protein degradation and the metabolic
state of the cells, has severe consequences and is associated with several pathophysiological
conditions, such as cancer.
The best-characterized regulator of autophagy is mTOR, which integrates growth factor and
nutrient signals to influence protein synthesis, growth, autophagy, and ribosomal biogenesis.
M-TOR occurs in two multiprotein complexes, mTORC1, containing the specific binding
proteins raptor and PRAS40, and mTORC2 containing rictor and other binding partners [38].
When nutrients are available, mTORC1 phosphorylates Unc-51-like kinase (ULK1) and ATG13
to block autophagy initiation. When nutrients are scarce, mTORC1 dissociates from the ULK1
complex, initiating the autophagy process [15, 40]. The initiation of autophagy occurs with the
assembly of the double-membrane phagophore, the precursor of the autophagosome. This
requires the formation of a protein complex constituted by Class III phosphatidylinositol 3-
kinase (PtdIns3K) and the proteins VPS34, p150, ATG14, and BECLIN 1. In tumors, autophagy
is stimulated by metabolic stress (e.g., nutrient/growth factor deprivation, hypoxia, and
acidosis), cellular damage, or inhibition of pro-survival signals caused by anticancer therapies
[41]. Through autophagy, cancer cells utilize a highly plastic and dynamic mechanism to either
repress initial steps of carcinogenesis or support the survival and growth of established tumors
[42, 43].
In multicellular organisms, autophagy also clears ubiquitinated or malfunctioning aggregated
proteins. This selective degradative process is mediated through the recognition of ubiquitin-
tagged cargos by the autophagy receptor p62/sequestosome 1 [44]. This protein directs them
to the autophagosome through concomitant binding to the LC3 (microtubule associated
protein 1 light chain 3) molecules localized at the inner and outer autophagosome membranes.
Autophagy is responsible for the degradation of p62, and therefore, when autophagy is
inhibited, p62 accumulates in mammalian cells.
Autophagy facilitates cancer cell resistance to chemotherapy treatment, and the inhibition of
autophagy may potentiate the resensitization of therapeutic-resistant cancer cells to anticancer
drugs. Chemotherapy treatment conferred resistance by triggering key autophagy signaling
molecules in malignant cells. For example, in response to irinotecan, pro-survival autophagy
was induced by activating MAPK14/p38 signaling, which lead to drug resistance [45]. It is
likely that protective autophagy in 5-Fluouracil (5-FU) resistance occurs through c-Jun N-
terminal Kinase (JNK) activation [46]. Given the propensity of PI3K-mTOR inhibition to
robustly induce autophagy, increased autophagic flux is a suspect contributor to the modest
efficacy of PI3K inhibitors. Several recent studies have provided evidence that combined
inhibition of autophagy and PI3K inhibitors or a combination therapy with a mTORC1
inhibitor (temsirolimus) and autophagy inhibitor [hydroxychloroquine (HCQ)] can sensitize
cells to chemotherapeutic agents [15, 47]. Several other trials that combine HCQ with radiation
therapy or chemotherapeutic agents have also been used on the basis of the accumulating
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preclinical evidence supporting the notion that increased autophagy promotes therapy-
induced resistance in tumor cells.
Examining the role of autophagy in RAS- and BRAF-induced transformation in colon cancer
cell lines, Goulielmaki et al. [20] found that the MEK/ERK pathway can increase the protein
levels of LC3, unlike the AKT/MTOR pathway, which has been shown to abolish the auto‐
phagic process. They showed that using specific autophagy inhibitors not only cancer cell
proliferation rate can be reduced, but the otherwise resistant mutant BRAF colon cell lines to
targeted BRAF agents, like PLX4720 (Vemurafenib), can be sensitized to apoptosis in a
synergistic manner. This study proposed a promising rational combinatorial treatment using
BRAF and autophagy inhibitors that will potentially provide efficient therapeutic protocols
for these otherwise untreatable tumors.
6. Contribution of stem cells to resistance
The intestinal epithelium is an example of self-renewing tissue on expense of stem cells that
reside at the crypt bottom. Tumor growth is sustained by a subpopulation of highly malignant
cancer stem cells (CSCs) or tumor-initiating cells, which are characterized by a life-long
capacity to self-renew, are multipotent, and can reversibly enter quiescent or even dormant
states and resist cytotoxic drugs [48]. Successful treatment is thus dependent on the selective
elimination of these highly resistant subpopulations, instead of only the main tumor mass.
Over the past decade, several cell surface markers have been identified in these cell popula‐
tions. CD133, Lgr5, and CD44 are the most frequently proposed stem cell markers in colorectal
cancer, but their distribution differs between patients and tumor cell lines [48, 49].
CD133 (also called prominin-1) is a pentaspan transmembrane glycoprotein identified as cell
surface stem cell marker that has been associated with tumorigenicity and progression of colon
cancer [50], but its precise role and functions are unknown. CD44 is a transmembrane glyco‐
protein involved in cell-cell and cell-matrix adhesion through its affinity for hyaluronic acid.
CD44 is encoded by a single gene, including 20 exons. The standard form, expressed in normal
adult stem cells (referred to as CD44), consists of exons 1–5 and 15–20. Importantly, it has been
demonstrated that cancer cells express different exon variants, such as CD44v6, produced by
alternative splicing mRNA processing [48]. Thus, universal targeting of CD44 might be
deleterious for patients and they can be avoided targeting different isoforms of CD44.
Several studies have implicated the potential contribution of a subpopulation of stem-like
progenitor cells in resistance to both chemotherapeutic and targeted therapies [51]. Various
groups have characterized the drug-resistant aspects of such stem-like subpopulations,
including a quiescent state refractory to agents targeting rapidly dividing cells, enhanced DNA
damage repair mechanisms, and decreased apoptotic machinery [52]. Recent studies have
implicated a potential mechanistic link between EGFR activation and the acquisition of stem-
like properties including the increase in known stem cell markers and enhanced spheroid
formation [53]; however, the role of EGFR in promoting stem cell properties in CRC has not
been fully characterized.
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The radioresistance of cancer stems cells has been supported by several research groups in
glioma and head and neck, breast, pancreatic, and colorectal cancer [48, 54]. Radiation itself
has also been shown to increase the expression of AKT and CD133 and reduce the expression
of CD44 in colorectal cancer cells [55]. Sahlberg et al. [48] found that cells with a CD44high/
CD133high expression demonstrated a higher radioresistance compared to CD44low/
CD133low cells and that different AKT isoforms have varying effects on the expression of
cancer stem cell markers, which is an important consideration when targeting AKT in a clinical
setting.
There is experimental evidence that hypoxia is associated with the maintenance and formation
of CSCs, promoting their phenotype and tumorigenesis [56]. It has also been shown that
hypoxia, by means of HIF-1α activation, is capable of maintaining CSCs phenotype in colon
cancer cells [57]. However, it has been recognized that the resident microenvironment of cancer
cells, also known as a “niche,” plays an important role in the genetic instability, metastasis,
and therapeutic resistance of CSCs [25]. Mao et al. [58] demonstrated that most CD133+ colon
CSCs are located in a hypoxic niche, where oxaliplatin, rather than 5-FU, inhibits proliferation
of these colon CSC cells. Recently several drugs have discovered to be selective against CSC.
Examples of them are microbe-derived and plant-derived biomolecules; small inhibitors that
target key signaling pathways of CSCs such as metformin, tranilast, and thioridazine; and also
antibodies directed against CSC-specific cell surface molecules, such as the CD44, CD47,
EpCAM, CD123, GD2, Lgr5, IGF-IR, Dll4, and FZD receptors [59].
7. Microvesicles: devices of intercellular communication
It has been demonstrated recently that challenging cancer cells with stresses that they would
typically encounter during tumor progression, or as a part of a therapeutic regiment to treat
or manage the disease, increase the rate of microvesicles (MVs referred also as oncosomes or
exosomes), formation, and shedding by cells [5–7]. Interestingly, the noncanonical Wnt
signaling pathways PCP and Wnt/Ca2+ appear to be involved in the regulation of MV biogen‐
esis and budding in human cancer cells, since one of their downstream effectors, the Rho
subfamily GTPase, that induce cell spreading and migration, has been demonstrated to
promote the rearrangements of the actin cytoskeleton to stimulate MV budding [60, 61].
MVs generally range in size from 0.1 to 2 μm in diameter. In addition to containing conven‐
tional paracrine signaling molecules, such as growth factors and pro-inflammatory cytokines,
MVs also contain membrane-associated, cytosolic, and nuclear molecules not normally
released by normal cells such as metabolic enzymes, metalloproteases, molecular chaperones,
and miRNAs and RNA transcripts [6, 7]. The uptake of MVs by cells has the potential to protect
them from a variety of apoptotic challenges by up-regulating the expression and/or activation
of proteins that work to counter the actions of cell death machinery. That is why recent findings
suggesting that MVs can promote cell survival and contribute to drug resistance are possibly
of significant value.
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In addition, because cancer cell-derived MVs often contain oncogenic proteins that reflect their
cell of origin, and their abundance and protein concentration correlate with the tumor grade/
aggressiveness, they have been converted in the focus for searching cancer biomarkers and/or
for monitoring tumor progression.
8. Concluding remarks
Mammalian cells coordinate cell metabolism and growth with environmentally induced stress.
In cancer cells, survival signaling cascades, metabolism, and autophagy are corrupted and
work in a highly integrated network to cope with stressful conditions such as hypoxia, limited
nutrients, and drugs, in order to maintain viability and proliferative activity.
Understanding the signaling networks that contribute to cancer cell survival and how the
changes in those networks allow cells to adapt in the presence of drugs that target key
components implicated in cancer cell survival and proliferation is the challenge. Thus, we are
hopeful that a better understanding of the signaling pathways involved and the development
of strategies to inhibit autophagy and/or hypoxia represent a new approach to enhance the
efficacy of cancer therapy to overcome therapeutic resistance in cancer cells.
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